Adriann Sax has been an advocate and practitioner of innovative thinking and strategic growth for the Life Sciences industry over her 25+ year career leading Strategy, Business Development and Commercial Initiatives globally in pharmaceuticals, biotech and devices. She is currently CEO of Orsenix, LLC a clinical stage, biotech developing a Phase 3 ready oral form of arsenic trioxide (ORH-2014) to treat a range of hematologic malignancies. Prior to Orsenix, Adriann held the position of Entrepreneur in Residence at Fortress Biotech, an accelerator that invests in and licenses early stage drugs and forms start-up biotech companies. She spent five years as EVP, Chief Commercial Officer, Kadmon Inc., transforming and leading all aspects of the commercial business. Before Kadmon, Adriann was EVP, BD and Strategy, for King Pharmaceuticals, where she developed and implemented a renewed, growth strategy leading to the company’s sale to Pfizer in 2010 for $6.5B. Adriann started her career at Sterling Drug progressing through a series of management and executive roles with established companies such as Merck, Bristol-Myers Squibb and Roche, and led the global launches of leading oncology and immunology drugs.
Adriann holds an MBA from the Keller Graduate School and BS from the University of Delaware. She’s an advisor and board member for industry associations, academic institutions and non-public company boards.